Get the Stockscreener App
1.66
3.49%
-0.06
After Hours:
1.76
0.10
+6.02%
Gain Therapeutics Inc stock is traded at $1.66, with a volume of 507.57K.
It is down -3.49% in the last 24 hours and up +8.50% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.72
Open:
$1.73
24h Volume:
507.57K
Relative Volume:
1.33
Market Cap:
$59.67M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.5091
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-5.68%
1M Performance:
+8.50%
6M Performance:
-21.33%
1Y Performance:
+12.93%
1-Day Range:
$1.65
$1.7488
1-Week Range:
$1.65
$1.805
52-Week Range:
$1.36
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.66 | 62.19M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Forecasting Gain Therapeutics Inc. price range with options dataJuly 2025 Selloffs & Expert-Curated Trade Recommendations - Newser
How to use Fibonacci retracement on Gain Therapeutics Inc.July 2025 Market Mood & Reliable Entry Point Alerts - Newser
Live market analysis of Gain Therapeutics Inc.Trade Analysis Summary & Short-Term Trading Alerts - Newser
Historical volatility pattern of Gain Therapeutics Inc. visualizedMarket Growth Report & Safe Capital Growth Trade Ideas - Newser
Is Gain Therapeutics Inc. showing signs of accumulationEarnings Risk Report & Reliable Volume Spike Alerts - Newser
Custom watchlist performance reports with Gain Therapeutics Inc.Weekly Market Outlook & Weekly Stock Performance Updates - Newser
Is this a good reentry point in Gain Therapeutics Inc.July 2025 Trade Ideas & Entry Point Confirmation Signals - Newser
Technical signs of recovery in Gain Therapeutics Inc.Earnings Risk Report & Precise Trade Entry Recommendations - Newser
Using Ichimoku Cloud for Gain Therapeutics Inc. technicals2025 Dividend Review & Community Driven Trade Alerts - Newser
Order flow analysis tools used on Gain Therapeutics Inc.Weekly Trade Recap & Fast Entry Momentum Trade Alerts - Newser
Best data tools to analyze Gain Therapeutics Inc. stockMarket Growth Review & Weekly Return Optimization Alerts - Newser
What the charts say about Gain Therapeutics Inc. today2025 Market Sentiment & Growth Focused Investment Plans - Newser
Developing predictive dashboards with Gain Therapeutics Inc. dataEarnings Overview Report & Long Hold Capital Preservation Plans - Newser
Price action breakdown for Gain Therapeutics Inc.Market Volume Report & Free Low Drawdown Momentum Trade Ideas - Newser
Gain Therapeutics (NASDAQ:GANX) Given "Buy" Rating at BTIG Research - MarketBeat
What’s next for Gain Therapeutics Inc. stock priceWall Street Watch & Weekly Top Stock Performers List - Newser
Is now a turning point for Gain Therapeutics Inc.2025 Market Overview & Verified Swing Trading Watchlists - Newser
Gain Therapeutics Inc. stock volume spike explainedQuarterly Earnings Report & Safe Capital Growth Tips - Newser
Ranking Gain Therapeutics Inc. among high performing stocks via toolsMarket Risk Analysis & Low Risk High Reward Trade Ideas - Newser
Is Gain Therapeutics Inc. stock trending bullishPortfolio Risk Report & Reliable Intraday Trade Alerts - Lancaster City Council
What indicators show strength in Gain Therapeutics Inc.Earnings Performance Report & Risk Managed Trade Strategies - Newser
What Fibonacci levels say about Gain Therapeutics Inc. reboundJuly 2025 Levels & Low Risk Entry Point Guides - Newser
Gain Therapeutics Inc. recovery potential after sell offPrice Action & Precise Trade Entry Recommendations - Newser
Applying chart zones and confluence areas to Gain Therapeutics Inc.2025 Market WrapUp & Verified Momentum Stock Watchlist - Newser
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from BTIG Research - Defense World
what analysts say about gain therapeutics inc. stock outlookWeekly Risk Report & AI Powered Buy and Sell Recommendations - Newser
Published on: 2025-09-09 05:54:14 - Newser
Is a relief rally coming for Gain Therapeutics Inc. holdersWeekly Trade Report & Community Shared Stock Ideas - Newser
Published on: 2025-09-08 20:10:41 - Newser
Chartists See Breakout Potential in Gain Therapeutics Inc.2025 Volatility Report & Consistent Profit Focused Trading Strategies - beatles.ru
What drives Gain Therapeutics Inc.’s stock priceGap Down & Verified Short-Term Plans - 강소기업뉴스
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):